Is AXSM or BBOT more undervalued in 2026?

CirclFi compares Axsome Therapeutics, Inc. (AXSM) and BridgeBio Oncology Therapeutics (BBOT) using 13 institutional-grade valuation models. AXSM has a Quality of Company score of 6.1/10 while BBOT scores 6.2/10.

Which is a better buy — AXSM or BBOT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AXSM and BBOT valuations compare?

AXSM at $232.83 and BBOT at $8.84 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AXSM vs BBOT Valuation Comparison 2026 — Intrinsic Value Analysis

AXSM

Biotechnology

Axsome Therapeutics, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$232.83

Last close

Models

12/13

Active

BBOT

Biotechnology

BridgeBio Oncology Therapeutics

Quality

6.2

out of 10

Value Trap

—

Price

$8.84

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	AXSM Fair Value	AXSM Upside	BBOT Fair Value	BBOT Upside
Bayesian DCF	Intrinsic	$79.80	-65.7%	$2.70	-69.5%
Earnings Power Value	Intrinsic	$82.92	-55.4%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.06	-98.7%	$3.92	-55.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AXSM vs BBOT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AXSM vs BBOT — Which Stock Is More Undervalued?

BBOT scores higher with a 6.2/10 quality rating vs AXSM's 6.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Axsome Therapeutics, Inc. (AXSM) and BridgeBio Oncology Therapeutics (BBOT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AXSM currently trades at $232.83 with a QOC of 6.1/10, while BBOT trades at $8.84 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).